



Issue Date: 9 February

TauRx and GT Diagnostics to present insights on the Alzheimer's patient journey at Dementias 2023

TauRx Pharmaceuticals Ltd., a global leader in Tau-based research in Alzheimer's disease (AD), and GT Diagnostics will share key insights related to the AD patient journey and advances in diagnostics and treatment during a presentation at the Dementias 2023 conference, taking place in London, United Kingdom from 9-10 February 2023.

The presentation, titled "The Alzheimer's Journey: Reflections on What Matters Most to Patients, Caregivers, Physicians," will shed new light on challenges people with Alzheimer's face along their disease journey, explain how people living with Alzheimer's and their families can become more empowered to make crucial decisions related to care, and highlight recent advancements in diagnosis and treatment. Panelists from TauRx and GT Diagnostics will deliver the presentation on 10 February at 10:30 GMT and will be on site at booth #2.

"Understanding the patient journey – particularly arriving at diagnosis, navigating complexities of caregiver and healthcare provider relationships, and making informed decisions when it comes to treatment – is of utmost importance to achieve optimal outcomes," explains Richard Stefanacci, MD, Chief Medical Officer at TauRx. "We look forward to sharing insights at Dementias 2023 to drive the conversation toward better patient outcomes and discussing our progress in addressing this global unmet need."

Alzheimer's dementia is a leading cause of death throughout the world and one of the most important public health issues to be addressed globally. TauRx aims to contribute to addressing this unmet need with data from its Phase 3 LUCIDITY trial and pursuit of Medicines and Healthcare products Regulatory Agency (MHRA) approval through the Innovative Licensing and Access Pathway (ILAP), having been granted an Innovation Passport, the first stage of the process, in May 2022.

For additional information, please visit: <https://taurx.com/> or <https://www.dementiasconference.com/>.

ABOUT LUCIDITY

LUCIDITY is the only late-stage clinical trial specifically targeting the tau pathology of Alzheimer's. Aggregation of abnormal tau protein is one of the hallmark pathologies.

Additional data analysis is ongoing in relation to the 1-year open label phase of the trial, secondary endpoints including MRI volumetric brain scans, and exploratory endpoints. A summary of the LUCIDITY study protocol has recently been published in The Journal of Prevention of Alzheimer's Disease (<http://dx.doi.org/10.14283/jpad.2022.63>).

<https://www.luciditytrial.com>

ABOUT TAURx PHARMACEUTICALS LTD

The TauRx group of companies was established in 2002 in Singapore, continuing a partnership with the University of Aberdeen, with primary research facilities and operation based in Aberdeen, UK. The company has dedicated the past two decades to developing treatments and diagnostics for Alzheimer's and other neurodegenerative diseases due to protein aggregation pathology.



Alzheimer's dementia is a leading cause of death throughout the world and one of the most important public health issues to be addressed globally. TauRx will contribute to addressing this unmet need with data from LUCIDITY and pursuit of regulatory approvals in line with its overall plans to commercialise HMTM and pursue clinical trials in other related neurodegenerative diseases. <https://www.taurx.com>

TAU PATHOLOGY IN ALZHEIMER'S

Through dedicated research programs, it is understood that certain age-related factors lead to misfolding and aggregation of tau proteins, and the subsequent formation of tau tangles in Alzheimer's. These tangles disrupt and damage neuronal function, a process that begins many years before symptoms of dementia are seen. Tau pathology has been proven to correlate with the clinical decline (loss of memory and ability to care for oneself) commonly seen in people with Alzheimer's, establishing it as an important target for treatment. HMTM is a tau aggregation inhibitor, which effectively crosses the blood brain barrier to target the source of this damaging process.

CONTACT

Rebecca Andersen
Head of Commercial and Communications
DL: +44 1224 440970
Email: r.andersen@taurx.com